Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{20bf4dfe007a48229c03a59dd2578db9,
title = "Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort",
abstract = "OBJECTIVE: The aim of this study was to report cases of medication-related osteonecrosis of the jaws (MRONJ) associated with targeted therapy (TT) with or without concomitant antiresorptive treatment, among the Copenhagen ONJ cohort, which includes all consecutive cases of MRONJ seen in Copenhagen.STUDY DESIGN: We retrospectively studied the treatment of 204 consecutive patients with MRONJ, seen between January 2010 and May 2016, to identify those associated with TT.RESULTS: We detected 7 cases of MRONJ associated with TT (3.4%). Four patients received TT only, whereas 3 were concomitantly treated with bisphosphonates (n = 3) and/or denosumab (n = 3). The TT regimens included sunitinib (Sutent) (n = 1), everolimus (Afinitor) (n = 1), erlotinib (Tarceva) (n = 1), bevacizumab (Avastin) (n = 3), dasatinib (Sprycel) (n = 1) and imatinib (Glivec) (n = 1). The MRONJ stage included stages 1 and 2, and mean score on the visual analogue scale for pain in the jaw was 4.0.CONCLUSIONS: Health care providers should be aware of the possibility of MRONJ associated with the TT agents sunitinib, everolimus, and dasatinib and uncommon cancer types, including renal cell carcinoma, non-small-cell lung cancer, glioblastoma, and leukemia, where MRONJ may also occur.",
keywords = "Aged, Aged, 80 and over, Antineoplastic Agents/adverse effects, Bisphosphonate-Associated Osteonecrosis of the Jaw/epidemiology, Bone Density Conservation Agents/adverse effects, Dasatinib/adverse effects, Denmark/epidemiology, Everolimus/adverse effects, Female, Humans, Indoles/adverse effects, Male, Middle Aged, Neoplasms/drug therapy, Pyrroles/adverse effects, Retrospective Studies, Sunitinib",
author = "{Abel Mahedi Mohamed}, Hoda and Nielsen, {Charlotte Emilie Nor} and Morten Schiodt",
note = "Copyright {\textcopyright} 2017 Elsevier Inc. All rights reserved.",
year = "2018",
month = feb,
doi = "10.1016/j.oooo.2017.10.010",
language = "English",
volume = "125",
pages = "157--163",
journal = "Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics",
issn = "2212-4403",
publisher = "Mosby, Inc",
number = "2",

}

RIS

TY - JOUR

T1 - Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort

AU - Abel Mahedi Mohamed, Hoda

AU - Nielsen, Charlotte Emilie Nor

AU - Schiodt, Morten

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - OBJECTIVE: The aim of this study was to report cases of medication-related osteonecrosis of the jaws (MRONJ) associated with targeted therapy (TT) with or without concomitant antiresorptive treatment, among the Copenhagen ONJ cohort, which includes all consecutive cases of MRONJ seen in Copenhagen.STUDY DESIGN: We retrospectively studied the treatment of 204 consecutive patients with MRONJ, seen between January 2010 and May 2016, to identify those associated with TT.RESULTS: We detected 7 cases of MRONJ associated with TT (3.4%). Four patients received TT only, whereas 3 were concomitantly treated with bisphosphonates (n = 3) and/or denosumab (n = 3). The TT regimens included sunitinib (Sutent) (n = 1), everolimus (Afinitor) (n = 1), erlotinib (Tarceva) (n = 1), bevacizumab (Avastin) (n = 3), dasatinib (Sprycel) (n = 1) and imatinib (Glivec) (n = 1). The MRONJ stage included stages 1 and 2, and mean score on the visual analogue scale for pain in the jaw was 4.0.CONCLUSIONS: Health care providers should be aware of the possibility of MRONJ associated with the TT agents sunitinib, everolimus, and dasatinib and uncommon cancer types, including renal cell carcinoma, non-small-cell lung cancer, glioblastoma, and leukemia, where MRONJ may also occur.

AB - OBJECTIVE: The aim of this study was to report cases of medication-related osteonecrosis of the jaws (MRONJ) associated with targeted therapy (TT) with or without concomitant antiresorptive treatment, among the Copenhagen ONJ cohort, which includes all consecutive cases of MRONJ seen in Copenhagen.STUDY DESIGN: We retrospectively studied the treatment of 204 consecutive patients with MRONJ, seen between January 2010 and May 2016, to identify those associated with TT.RESULTS: We detected 7 cases of MRONJ associated with TT (3.4%). Four patients received TT only, whereas 3 were concomitantly treated with bisphosphonates (n = 3) and/or denosumab (n = 3). The TT regimens included sunitinib (Sutent) (n = 1), everolimus (Afinitor) (n = 1), erlotinib (Tarceva) (n = 1), bevacizumab (Avastin) (n = 3), dasatinib (Sprycel) (n = 1) and imatinib (Glivec) (n = 1). The MRONJ stage included stages 1 and 2, and mean score on the visual analogue scale for pain in the jaw was 4.0.CONCLUSIONS: Health care providers should be aware of the possibility of MRONJ associated with the TT agents sunitinib, everolimus, and dasatinib and uncommon cancer types, including renal cell carcinoma, non-small-cell lung cancer, glioblastoma, and leukemia, where MRONJ may also occur.

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents/adverse effects

KW - Bisphosphonate-Associated Osteonecrosis of the Jaw/epidemiology

KW - Bone Density Conservation Agents/adverse effects

KW - Dasatinib/adverse effects

KW - Denmark/epidemiology

KW - Everolimus/adverse effects

KW - Female

KW - Humans

KW - Indoles/adverse effects

KW - Male

KW - Middle Aged

KW - Neoplasms/drug therapy

KW - Pyrroles/adverse effects

KW - Retrospective Studies

KW - Sunitinib

U2 - 10.1016/j.oooo.2017.10.010

DO - 10.1016/j.oooo.2017.10.010

M3 - Journal article

C2 - 29221983

VL - 125

SP - 157

EP - 163

JO - Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

JF - Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

SN - 2212-4403

IS - 2

ER -

ID: 56437901